MiMedx Group Inc (MDXG)
NASDAQ: MDXGHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MDXG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $445.07M
- Forward P/E
- 122.00
- EPS (TTM)
- -$0.13
- Dividend yield
- None
- 52-week range
- 3.03 – 7.45
- Day range
- 3.03 – 3.14
- Volume / Avg
- 2.12M / 1.39M
- Beta
- —
- Shares outstanding
- 145.93M
52-week range
MDXG stock today
On Nov 20, MDXG ended the session at $3.05, shedding $0.06 (1.93%), versus the S&P 500's 3.70% decline. At this level, MDXG sits near the bottom of its 52-week range of $3.03 to $7.45: 59.1% below the high, set on Dec 18, 2025 and 0.7% above the low. MDXG is down 54.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 54.9%.
MiMedx Group has posted a net loss over the last twelve months (EPS of -$0.13), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About MiMedx Group
Company profileMiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Joseph H. Capper
- Headquarters
- Marietta, GA
- Employees
- 808
- Website
- mimedx.com
Financial highlights
Full financialsIn fiscal 2025, MiMedx Group generated $418.6 million in revenue, up 20.0% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $48.6 million (+14.5% year over year), for a net margin of 11.6% versus a median of -4.2% in the prior 5 years. Gross margin was 82.6% (down from 82.8%) and operating margin 15.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $418.63M | $348.88M | $321.48M | $267.84M | $242.02M |
| Growth | +19.99% | +8.52% | +20.03% | +10.67% | -2.50% |
| Net income | $48.58M | $42.42M | $58.23M | $-30.20M | $-10.29M |
| EPS (diluted) | $0.32 | $0.28 | $0.37 | $-0.33 | $-0.15 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$7.00+129.51%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $-0.06 vs —
MDXG news
All MDXG news- MIMEDX to Participate in Upcoming Investor ConferencesGlobeNewswire
- MiMedx (MDXG) Q3 2026 Earnings Call TranscriptNasdaq
- MiMedx outlines $250M-$260M 2026 net sales as it targets >20% adjusted EBITDA margin with SanaraSeeking Alpha
- MiMedx Group, Inc. Reports Third Quarter 2026 Results and $25 million Patent License AgreementNasdaq
- MIMEDX announces $25M patent license agreementSeeking Alpha
- MIMEDX Announces Third Quarter 2026 Operating & Financial ResultsGlobeNewswire
- MIMEDX Announces $25 Million Patent License AgreementGlobeNewswire
- Sanara MedTech/MiMedx deal spread widens on FTC second requestSeeking Alpha
MiMedx Group peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ANGOAngioDynamics Inc. | 10.81 | +0.46% | $454.61M | vs MDXG |
| SENSSenseonics Holdings Inc. | 8.02 | -9.94% | $439.34M | vs MDXG |
| CARLCarlsmed Inc. | 17.42 | +1.16% | $477.38M | vs MDXG |
| SIShoulder Innovations Inc. | 20.15 | -0.79% | $421.58M | vs MDXG |
| RCELAvita Medical Inc. | 15.62 | -2.31% | $494.96M | vs MDXG |
| MOBIMobia Medical Inc. | 11.85 | -0.08% | $394.50M | vs MDXG |
| CERSCerus Corporation | 1.85 | -2.63% | $373.62M | vs MDXG |
| SGHTSight Sciences Inc. | 10.18 | -4.14% | $565.79M | vs MDXG |
Indexes, lists and sector
MiMedx Group stock FAQ
What is MiMedx Group's stock price today?
MDXG last traded at $3.05 as of Nov 20, 4:00 PM EST, down 1.93% on the day. Prices are delayed at least 15 minutes.
Does MiMedx Group pay a dividend?
No. MiMedx Group does not currently pay a regular cash dividend.
Who is MiMedx Group's CEO?
Mr. Joseph H. Capper is the chief executive officer of MiMedx Group Inc, which has about 808 employees.
Has MDXG ever split its stock?
Yes. The most recent MDXG stock split was a 3235-for-10000 split on Apr 2, 2008.
What is the MDXG 52-week high?
The 52-week high for MDXG is $7.45 and the 52-week low is $3.03. The stock is currently 59.1% below its high.